Education
About Us
Working with TipRanks
Follow Us
Sigyn Therapeutics (SIGY)
OTHER OTC:SIGY
Total Valuation
Sigyn Therapeutics has a market cap or net worth of $4.43M. The enterprise value is ―.
Market Cap$4.43M
Enterprise Value―
Share Statistics
Sigyn Therapeutics has 1,605,377 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,605,377
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sigyn Therapeutics’s return on equity (ROE) is 0.75 and return on invested capital (ROIC) is 111.21%.
Return on Equity (ROE)0.75
Return on Assets (ROA)-15.63
Return on Invested Capital (ROIC)111.21%
Return on Capital Employed (ROCE)0.57
Revenue Per Employee0.00
Profits Per Employee-835.05K
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sigyn Therapeutics is ―. Sigyn Therapeutics’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio-0.94
Price to Fair Value-0.94
Price to FCF-4.81
Price to Operating Cash Flow-8.20
PEG Ratio0.04
Income Statement
In the last 12 months, Sigyn Therapeutics had revenue of 0.00 and earned -3.34M in profits. Earnings per share was -2.51.
Revenue0.00
Gross Profit0.00
Operating Income-2.52M
Pretax Income-3.34M
Net Income-3.34M
EBITDA-2.52M
Earnings Per Share (EPS)-2.51
Cash Flow
In the last 12 months, operating cash flow was -900.91K and capital expenditures -4.00, giving a free cash flow of -900.92K billion.
Operating Cash Flow-900.91K
Free Cash Flow-900.92K
Free Cash Flow per Share-0.56
Dividends & Yields
Sigyn Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.57
52-Week Price Change-47.43%
50-Day Moving Average3.37
200-Day Moving Average3.40
Relative Strength Index (RSI)33.38
Average Volume (3m)879.00
Important Dates
Sigyn Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Sigyn Therapeutics as a current ratio of <0.01, with Debt / Equity ratio of -47.26%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap0.49
Net Debt to EBITDA-0.87
Interest Coverage Ratio-2.93
Taxes
In the past 12 months, Sigyn Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Sigyn Therapeutics EV to EBITDA ratio is -2.53, with an EV/FCF ratio of -7.31.
EV to Sales0.00
EV to EBITDA-2.53
EV to Free Cash Flow-7.31
EV to Operating Cash Flow-7.31
Balance Sheet
Sigyn Therapeutics has $459.00 in cash and marketable securities with $2.57M in debt, giving a net cash position of -$2.57M billion.
Cash & Marketable Securities$459.00
Total Debt$2.57M
Net Cash-$2.57M
Net Cash Per Share-$1.60
Tangible Book Value Per Share-$3.35
Margins
Gross margin is 26.39%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin26.39%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Sigyn Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast15.75%